Anzeige
Mehr »
Donnerstag, 01.01.2026 - Börsentäglich über 12.000 News
Schon +250% im Plus - warum diese Goldstory gerade erst startet!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BDZ | ISIN: KYG2545C1042 | Ticker-Symbol: C68
Frankfurt
30.12.25 | 08:06
9,500 Euro
-2,06 % -0,200
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CRESCENT BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
CRESCENT BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,50011,10030.12.25

Aktuelle News zur CRESCENT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.12.25Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards3
05.12.25China's Kelun-Biotech to Earn More Than USD1.3 Billion From Cancer Drugs Licensing Deal With US' Crescent Bio3
04.12.25Crescent Biopharma stock price target raised by Stifel to $32 on Kelun deal1
04.12.25Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance2
04.12.25Partnerschaft mit Kelun-Biotech und Privatplatzierung beflügeln Aktie von Crescent Biopharma1
CRESCENT BIOPHARMA Aktie jetzt für 0€ handeln
04.12.25Morning Market Movers: Polyrizon, Picard Medical, Crescent Biopharma, Hyster-Yale See Big Swings375OTTAWA (dpa-AFX) - At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
04.12.25Crescent Biopharma partners with Kelun-Biotech, raises $185 million4
04.12.25Kelun-Biotech and Crescent Biopharma form oncology partnership5
04.12.25CRESCENT BIOPHARMA, INC. - 8-K, Current Report2
04.12.25Crescent Biopharma, Inc.: Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors176Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical...
► Artikel lesen
04.12.25Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics1
17.11.25Crescent Biopharma Announces Grants of Inducement Awards4
06.11.25Crescent Biopharma GAAP EPS of -$1.27 beats by $0.083
06.11.25Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights305IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the...
► Artikel lesen
06.11.25CRESCENT BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans1
06.11.25CRESCENT BIOPHARMA, INC. - 8-A12B/A, Registration of securities1
06.11.25CRESCENT BIOPHARMA, INC. - 10-Q, Quarterly Report1
06.11.25CRESCENT BIOPHARMA, INC. - 8-K, Current Report2
04.11.25Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting1
02.10.25XFRA C68: WIEDERAUFNAHME/RESUMPTION163FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1